Total Funding
89
78
Total FundingPost-IPO Equity raised
Growth Score
-4 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
9622
Biocytogen is a biopharmaceutical company that provides integrated solutions for antibody drug development.
- Yuelei Shen: Founder, President and CEOPast Role: The Howard Hughes Medical Institute, Postdoctoral fellow
Tianquan Jin: Vice PresidentPast Role: University of Illinois Chicago, Post Doctorate and Research Assistant Professor
About the Company
Biocytogen is a biopharmaceutical company that provides biomedical communities with integrated solutions for antibody drug development. Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMabTM Mouse), and in
vivo/in vitro preclinical validation studies, using gene editing technologies and a state-of-the-art animal facility. Biocytogen works with the world's leading pharmaceutical and biotechnology companies.
